A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 16, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CRL SEC filings page.
Charles River Laboratories International, Inc. (CRL) reported $4.0B in revenue over the twelve months to Sep 26, 2026, down 1.2% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is nearly flat, but profit has collapsed while cash generation holds up, revealing a business whose reported earnings and cash economics diverge.
In FY2025, operating cash flow was$738M despite a net loss of$144M , so the income statement and cash engine diverged sharply. Free cash flow remained$518M after capital spending, while depreciation and amortization reached$403M ; that non-cash expense helps explain why cash exceeds accounting profit.
The deterioration is margin-led rather than volume-led: revenue barely changed from FY2023 to FY2025, while operating margin fell 14.3 percentage points. SG&A was
The balance sheet is less debt-heavy than in FY2023: long-term debt fell
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Charles River Laboratories International, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. Charles River Laboratories International, Inc. scores 48/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. Charles River Laboratories International, Inc. scores 26/100 on it among other operating companies.
Charles River Laboratories International, Inc.'s net debt of $1.9B, being $2.1B of long-term debt less $213.8M of cash, came to 4.49 times its EBITDA in fiscal year 2025. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and Charles River Laboratories International, Inc. scores 17/100 among other operating companies measured the same way.
Charles River Laboratories International, Inc. held $1.29 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.29. Liquidity ranks operating companies on that ratio, and Charles River Laboratories International, Inc. scores 34/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. Charles River Laboratories International, Inc. scores 71/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. Charles River Laboratories International, Inc. scores 43/100 on it among other operating companies.
Charles River Laboratories International, Inc. scores 3.36, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $16.1B against total liabilities of $3.9B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Charles River Laboratories International, Inc. passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
Charles River Laboratories International, Inc. reported a net loss of $144.3M while generating $737.6M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Charles River Laboratories International, Inc. earns $0.24 in operating income for every $1 of interest expense ($25.2M vs $107.0M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Charles River Laboratories International, Inc. generated $982.7M in revenue in Q3 2026. This represents a decrease of 2.2% from the same quarter a year earlier. Against the prior quarter it is down 2.1%.
Charles River Laboratories International, Inc.'s EBITDA was $274.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 25.5% from the same quarter a year earlier. Against the prior quarter it is up 46.9%.
Charles River Laboratories International, Inc. reported $333.1M in net income in Q3 2026. This represents an increase of 512.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Charles River Laboratories International, Inc. earned $6.86 per diluted share (EPS) in Q3 2026. This represents an increase of 523.6% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Charles River Laboratories International, Inc. generated $207.3M in free cash flow in Q3 2026, representing cash available after capex. This represents an increase of 16.3% from the same quarter a year earlier. Against the prior quarter it is up 39.5%.
Charles River Laboratories International, Inc. held $200.4M in cash against $2.4B in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
Charles River Laboratories International, Inc.'s operating margin was 20.6% in Q3 2026, reflecting core business profitability. This is up 7.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 8.7 percentage points.
Charles River Laboratories International, Inc.'s net profit margin was 33.9% in Q3 2026, showing the share of revenue converted to profit. This is up 28.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 34.0 percentage points.
Charles River Laboratories International, Inc.'s quarterly ROE was 10.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 8.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 10.4 percentage points.
Not reported for Q3 2026.
Capital Allocation
Charles River Laboratories International, Inc. spent $224K on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 140.9% from the same quarter a year earlier. Against the prior quarter it is down 99.8%.
Charles River Laboratories International, Inc. invested $46.8M in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 31.6% from the same quarter a year earlier. Against the prior quarter it is up 50.5%.
Not reported for Q3 2026.
CRL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $982.7M-2.2% | $1.0B-2.7% | $995.8M+1.2% | $994.2M-0.8% | $1.0B-0.5% | $1.0B+0.6% | $984.2M-2.7% | $1.0B-1.1% |
| SG&A Expenses | $140.6M-20.8% | $228.9M+19.5% | $159.4M-10.3% | $196.1M+0.2% | $177.6M-10.9% | $191.5M+12.8% | $177.8M-4.6% | $195.7M-0.7% |
| Operating Income | $202.6M+51.4% | $119.9M+19.7% | $119.9M+60.6% | -$283.4Mn/m | $133.8M+14.0% | $100.1M-34.0% | $74.7M-40.7% | -$167.7M-226.2% |
| EBITDA | $274.9M+25.5% | $187.2M-14.8% | $187.0M-4.1% | -$205.2Mn/m | $219.0M+6.5% | $219.6M-7.6% | $195.0M-7.7% | -$65.6M-130.7% |
| Interest Expense | $28.5M+12.3% | $30.3M+1.2% | $26.7M-4.1% | $23.8M-15.8% | $25.4M-16.1% | $30.0M-8.6% | $27.9M-20.3% | $28.2M-15.8% |
| Income Tax | -$163.8M-617.6% | $53.9M+188.0% | -$15.1M-249.9% | -$17.8Mn/m | $31.6M+51.1% | $18.7M-26.3% | $10.1M-58.8% | -$3.0M-115.4% |
| Net Income | $333.1M+512.0% | -$1.5M-102.8% | -$14.8M-158.3% | -$276.6Mn/m | $54.4M-21.9% | $52.3M-44.4% | $25.5M-65.1% | -$214.5M-214.7% |
| EPS (Basic) | $6.97+527.9% | -$0.03-102.8% | -$0.30-160.0% | -$5.57n/m | $1.11-17.2% | $1.06-39.4% | $0.50-61.8% | -$4.19-214.8% |
| EPS (Diluted) | $6.86+523.6% | -$0.03-102.8% | -$0.30-160.0% | -$5.56n/m | $1.10-17.3% | $1.06-39.1% | $0.50-61.5% | -$4.17-214.6% |
| Diluted Shares (Avg) | 49M-1.7% | 48M-2.6% | 49M-3.7% | N/A | 49M-4.2% | 49M-4.9% | 51M-1.9% | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses.
CRL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.5B-0.8% | $7.5B-0.4% | $7.7B+2.0% | $7.1B-5.2% | $7.5B-6.1% | $7.6B-4.9% | $7.6B-7.0% | $7.5B-8.1% |
| Current Assets | $1.5B+0.2% | $1.5B+4.0% | $1.5B-1.2% | $1.4B+3.1% | $1.5B+2.5% | $1.5B-2.0% | $1.5B-9.7% | $1.4B-12.8% |
| Cash & Equivalents | $200.4M-3.2% | $192.0M+5.0% | $191.8M-16.4% | $213.8M+9.8% | $207.1M-1.5% | $182.8M+2.0% | $229.4M-29.9% | $194.6M-29.7% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $319.6M+5.6% | $346.3M+23.9% | $359.7M+24.0% | $299.1M+7.4% | $302.6M-10.0% | $279.6M-19.9% | $290.2M-19.7% | $278.5M-26.7% |
| Accounts Receivable | $735.3M+0.1% | $711.8M-7.3% | $700.3M-7.5% | $708.9M-1.7% | $734.5M-2.6% | $767.6M+0.7% | $756.6M-3.9% | $720.9M-7.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $3.1B+5.5% | $3.1B+4.8% | $3.0B+5.8% | $2.8B-2.9% | $2.9B-6.5% | $2.9B-4.7% | $2.9B-6.4% | $2.8B-8.0% |
| Total Liabilities | $4.2B+2.8% | $4.6B+11.6% | $4.7B+9.2% | $3.9B-2.4% | $4.1B-2.7% | $4.2B-0.3% | $4.3B-2.4% | $4.0B-11.4% |
| Current Liabilities | $1.1B-2.9% | $1.1B+5.0% | $1.1B+4.1% | $1.1B+12.7% | $1.1B+10.8% | $1.1B+14.0% | $1.1B+10.1% | $994.1M-5.8% |
| Non-Current Liabilities | $3.1B+5.0% | $3.5B+13.9% | $3.6B+10.9% | $2.8B-7.3% | $2.9B-7.0% | $3.1B-4.6% | $3.3B-5.9% | $3.0B-13.1% |
| Long-Term Debt | $2.4B+11.8% | $2.6B+12.3% | $2.7B+6.1% | $2.1B-4.6% | $2.2B-6.1% | $2.3B-3.2% | $2.5B-5.6% | $2.2B-15.4% |
| Total Equity | $3.2B-5.2% | $2.8B-15.3% | $2.9B-7.9% | $3.2B-8.6% | $3.4B-10.0% | $3.4B-9.9% | $3.2B-12.3% | $3.5B-3.8% |
| Retained Earnings | $1.7B-12.3% | $1.4B-27.4% | $1.4B-25.2% | $1.4B-23.4% | $1.9B-8.4% | $1.9B-8.0% | $1.8B-6.2% | $1.8B-4.0% |
CRL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $254.1M+18.8% | $179.7M-12.2% | $41.1M-76.1% | $147.5M-7.4% | $213.8M-15.1% | $204.6M+5.7% | $171.7M+32.2% | $159.4M-27.9% |
| Depreciation & Amortization | $72.3M-15.2% | $67.3M-43.7% | $67.2M-44.2% | $78.3M-23.3% | $85.2M-3.4% | $119.5M+38.8% | $120.4M+41.0% | $102.1M+26.8% |
| Stock-Based Compensation | N/A | N/A | $22.4M+70.4% | N/A | N/A | N/A | $13.1M-21.5% | N/A |
| Capital Expenditures | $46.8M+31.6% | $31.1M-11.9% | $55.9M-5.8% | $89.0M+17.6% | $35.6M-8.1% | $35.3M-10.6% | $59.3M-25.0% | $75.6M-3.5% |
| Free Cash Flow | $207.3M+16.3% | $148.6M-12.2% | -$14.8M-113.2% | $58.6M-30.1% | $178.2M-16.3% | $169.3M+9.9% | $112.4M+121.5% | $83.7M-41.3% |
| Investing Cash Flow | $10.2Mn/m | $28.1Mn/m | -$407.8Mn/m | -$92.8Mn/m | -$33.7Mn/m | -$37.3Mn/m | -$45.5Mn/m | -$76.1Mn/m |
| Financing Cash Flow | -$254.1Mn/m | -$164.7Mn/m | $347.7Mn/m | -$51.9Mn/m | -$152.6Mn/m | -$226.9Mn/m | -$105.3M-674.1% | -$75.9M-161.4% |
| Share Buybacks | $224K+140.9% | $115.6M+1472.3% | $208.3M-41.0% | $96K-22.6% | $93K-99.9% | $7.4M-17.5% | $353.1M+3676.4% | $124K-10.8% |
Not reported in any period shown, so not listed: Dividends Paid.
CRL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | 20.6%+7.3pp | 11.9%+2.2pp | 12.0%+4.5pp | -28.5%-11.8pp | 13.3%+1.7pp | 9.7%-5.1pp | 7.6%-4.9pp | -16.7%-29.8pp |
| Net Margin | 33.9%+28.5pp | -0.1%-5.2pp | -1.5%-4.1pp | -27.8%-6.4pp | 5.4%-1.5pp | 5.1%-4.1pp | 2.6%-4.6pp | -21.4%-39.8pp |
| Return on Equity | 10.3%+8.7pp | -0.1%-1.6pp | -0.5%-1.3pp | -8.7%-2.5pp | 1.6%-0.2pp | 1.6%-1.0pp | 0.8%-1.2pp | -6.2%-11.4pp |
| Return on Assets | 4.5%+3.8pp | 0.0%-0.7pp | -0.2%-0.5pp | -3.9%-1.0pp | 0.7%-0.1pp | 0.7%-0.5pp | 0.3%-0.5pp | -2.9%-5.1pp |
| Current Ratio | 1.410.0x | 1.350.0x | 1.36-0.1x | 1.29-0.1x | 1.37-0.1x | 1.36-0.2x | 1.43-0.3x | 1.41-0.1x |
| Debt-to-Equity | 0.76+0.1x | 0.92+0.2x | 0.91+0.1x | 0.680.0x | 0.640.0x | 0.700.0x | 0.79+0.1x | 0.65-0.1x |
| Liabilities-to-Equity | 1.29+0.1x | 1.64+0.4x | 1.61+0.3x | 1.24+0.1x | 1.19+0.1x | 1.24+0.1x | 1.36+0.1x | 1.16-0.1x |
| Asset Turnover | 0.130.0x | 0.130.0x | 0.130.0x | 0.140.0x | 0.130.0x | 0.140.0x | 0.130.0x | 0.130.0x |
| FCF Margin | 21.1%+3.4pp | 14.8%-1.6pp | -1.5%-12.9pp | 5.9%-2.5pp | 17.7%-3.4pp | 16.4%+1.4pp | 11.4%+6.4pp | 8.3%-5.7pp |
Not reported in any period shown, so not listed: Gross Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Charles River Laboratories International, Inc. CRL | FY2025 | $4.0B | -$144.3M | -3.6% | $16.1B | 40/100 |
| Revvity, Inc. RVTY | FY2025 | $2.9B | $241.2M | 8.5% | $16.6B | 52/100 |
| Medpace Holdings, Inc. MEDP | FY2025 | $2.5B | $451.1M | 17.8% | $18.1B | 60/100 |
| Icon Plc ICLR | FY2025 | $8.3B | $229.3M | 2.8% | $14.3B | 46/100 |
| Guardant Health, Inc. GH | FY2025 | $982.0M | -$416.3M | -42.4% | $19.5B | 68/100 |
| Qiagen N.V. QGEN | FY2025 | $2.1B | $424.9M | 20.3% | $10.3B | 66/100 |
Where Charles River Laboratories International, Inc. Ranks
Frequently Asked Questions
Charles River Laboratories International, Inc. (CRL) reported $4.0B in total revenue for fiscal year 2025. This represents a -0.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Charles River Laboratories International, Inc. (CRL) revenue declined by 0.9% year-over-year, from $4.0B to $4.0B in fiscal year 2025.
Yes, Charles River Laboratories International, Inc. (CRL) reported a net income of $40.2M over the trailing 12 months to September 26, 2026. In fiscal year 2025 it reported a net loss of $144.3M, with a net profit margin of -3.6%.
Charles River Laboratories International, Inc. (CRL) had EBITDA of $428.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, Charles River Laboratories International, Inc. (CRL) had $213.8M in cash and equivalents against $2.1B in long-term debt.
Charles River Laboratories International, Inc. (CRL) had an operating margin of 0.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Charles River Laboratories International, Inc. (CRL) had a net profit margin of -3.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Charles River Laboratories International, Inc. (CRL) has a return on equity of -4.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Charles River Laboratories International, Inc. (CRL) generated $518.5M in free cash flow during fiscal year 2025. This represents a 3.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Charles River Laboratories International, Inc. (CRL) generated $737.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
Charles River Laboratories International, Inc. (CRL) had $7.1B in total assets as of fiscal year 2025, including both current and long-term assets.
Charles River Laboratories International, Inc. (CRL) invested $219.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Charles River Laboratories International, Inc. (CRL) had a current ratio of 1.29 as of fiscal year 2025, which is considered adequate.
Charles River Laboratories International, Inc. (CRL) had a debt-to-equity ratio of 0.68 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
Charles River Laboratories International, Inc. (CRL) had a liabilities-to-equity ratio of 1.24 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
Charles River Laboratories International, Inc. (CRL) had a return on assets of -2.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Charles River Laboratories International, Inc. (CRL) trades at 400x earnings, its market capitalization divided by $40.2M net income, trailing 12 months to September 26, 2026. The market capitalization is $16.1B as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Charles River Laboratories International, Inc. (CRL) trades at 4.0x sales, its market capitalization divided by $4.0B revenue, trailing 12 months to September 26, 2026. The market capitalization is $16.1B as of Nov 16, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Charles River Laboratories International, Inc. (CRL) has an Altman Z-Score of 3.36, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Charles River Laboratories International, Inc. (CRL) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Charles River Laboratories International, Inc. (CRL) reported a net loss of $144.3M while generating $737.6M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Charles River Laboratories International, Inc. (CRL) has an interest coverage ratio of 0.24x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
Charles River Laboratories International, Inc. (CRL) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.